205 related articles for article (PubMed ID: 20605106)
1. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease.
Schnitzler A; Leffers KW; Häck HJ
Parkinsonism Relat Disord; 2010 Sep; 16(8):513-6. PubMed ID: 20605106
[TBL] [Abstract][Full Text] [Related]
2. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
[TBL] [Abstract][Full Text] [Related]
4. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.
Woitalla D; Kassubek J; Timmermann L; Lauterbach T; Berkels R; Grieger F; Müller T
Parkinsonism Relat Disord; 2015 Mar; 21(3):199-204. PubMed ID: 25595315
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
[TBL] [Abstract][Full Text] [Related]
6. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.
Giladi N; Boroojerdi B; Korczyn AD; Burn DJ; Clarke CE; Schapira AH;
Mov Disord; 2007 Dec; 22(16):2398-404. PubMed ID: 17935234
[TBL] [Abstract][Full Text] [Related]
8. Rotigotine for the treatment of Parkinson's disease.
Morgan JC; Sethi KD
Expert Rev Neurother; 2006 Sep; 6(9):1275-82. PubMed ID: 17009915
[TBL] [Abstract][Full Text] [Related]
9. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
11. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
12. High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease.
Rektor I; Babic T; Boothmann B; Polivka J; Boroojerdi B; Randerath O
Clin Neuropharmacol; 2009; 32(4):193-8. PubMed ID: 19644228
[TBL] [Abstract][Full Text] [Related]
13. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
[TBL] [Abstract][Full Text] [Related]
14. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Boroojerdi B; Wolff HM; Braun M; Scheller DK
Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
[TBL] [Abstract][Full Text] [Related]
15. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
Watts RL; Jankovic J; Waters C; Rajput A; Boroojerdi B; Rao J
Neurology; 2007 Jan; 68(4):272-6. PubMed ID: 17202432
[TBL] [Abstract][Full Text] [Related]
16. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Giladi N; Boroojerdi B; Surmann E
J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
[TBL] [Abstract][Full Text] [Related]
18. The development of the rotigotine transdermal patch: a historical perspective.
Waters C
Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953
[TBL] [Abstract][Full Text] [Related]
19. Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.
Ohta K; Osada T
Clin Neuropharmacol; 2015; 38(6):231-5. PubMed ID: 26536020
[TBL] [Abstract][Full Text] [Related]
20. Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhang ZX; Liu CF; Tao EX; Shao M; Liu YM; Wang J; Asgharnejad M; Xue HB; Surmann E; Bauer L
Parkinsonism Relat Disord; 2017 Nov; 44():6-12. PubMed ID: 28827011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
